Currently, only three officially approved biomarkers were used to guide the clinical application of PD‐1 antibody monotherapy, including PD‐L1 expression, microsatellite instability (MSI) status and tumor mutational burden (TMB),12 with moderate predictive performance. Here, PDCD1 is linked to neoplasm.